伊马替尼治疗胃肠间质瘤并瘢痕疙瘩增生一例  

The treatment of gastrointestinal stromal tumor with imatinib lead to hyperplasia of keloid

作　　者：周永建[1] 郑伟军 林国生[1] Zhou Yongjian;Zheng Weijun;Lin Guosheng(Department of Gastric Surgery,Union Hospital Affiliated to Fujian Medical University,Fuzhou 350001,China)

机构地区：[1]福建医科大学附属协和医院胃外科

出　　处：《中华结直肠疾病电子杂志》2019年第3期301-303,共3页Chinese Journal of Colorectal Diseases(Electronic Edition)

基　　金：福建省卫生计生中青年骨干人才培养项目(No.2016-ZQN-24);2016年福建省科技厅对外合作项目(No.2018I0008)

摘　　要：甲磺酸伊马替尼是一种选择性酪氨酸激酶抑制剂,能在细胞水平上抑制bcr-abl、PDGF受体、SCF、c-Kit等受体的酪氨酸激酶,抑制细胞增殖、诱导细胞凋亡,是治疗胃肠道间质瘤一线药物。最常见的不良反应有水肿、皮疹、疲劳、恶心、中性粒细胞减少,但其促进患者瘢痕疙瘩增生尚未有报道,现报道如下。Imatinib mesylate is a selective tyrosine kinase inhibitor that inhibits the tyrosine kinase of bcr-abl, PDGF receptor, SCF, c-kit and other receptors at the cellular level. It Inhibits cell proliferation and induces apoptosis. Imatinib is the first-line drug for the treatment of gastrointestinal stromal tumor. The most common adverse reactions of Imatinib are edema, skin rash, fatigue, nausea and neutropenia, But the induction about hyperplasia of keloid in patients has not been reported. This case suggests that imatinib may lead to hyperplasia of skin keloid, possibly by influencing the immune system of patients with gastrointestinal stromal tumor.

关 键 词：胃肠间质瘤 伊马替尼 瘢痕疙瘩 

分 类 号：R735[医药卫生—肿瘤]